Candida parapsilosis is a yeast-like fungus that ranks among the leading causes of bloodstream infections acquired in hospitals, particularly in patients with central venous catheters, premature newborns, and people with weakened immune systems. Unlike its better-known relative Candida albicans, C. parapsilosis has a particular talent for clinging to plastic medical devices and spreading through the hands of healthcare workers, which makes it a persistent problem in intensive care units worldwide. Its infections range from relatively mild nail disease to life-threatening bloodstream invasion, and rising drug resistance in recent years has complicated what used to be a fairly straightforward treatment picture.
Where C. Parapsilosis Infections Happen
This organism is overwhelmingly a hospital-acquired problem. It thrives in healthcare environments, and its ability to colonize catheters, feeding lines, and other implanted devices gives it a direct route into the bloodstream.1PubMed Central. Epidemiologic and molecular characterization of an outbreak of Candida parapsilosis bloodstream infections in a community hospital Rates of C. parapsilosis bloodstream infection climbed during the COVID-19 pandemic, peaking at roughly 10 per 100,000 hospitalizations in 2020–2021 in the United States, with the highest burden among adults aged 45–64.2Medical Mycology. Hospitalizations involving Candida parapsilosis bloodstream infection, United States, 2016–2024 That spike likely reflected the surge in critically ill patients requiring prolonged catheter use, heavy antibiotic exposure, and extended ICU stays during the pandemic.
Neonatal intensive care units are another hotspot. Premature infants, especially those with very low birthweight, face elevated risk because they require assisted ventilation, long-dwelling intravenous lines, and broad-spectrum antibiotics that wipe out competing bacteria and create space for fungi to grow.3PubMed Central. Risk factors for Candida parapsilosis bloodstream infection in a neonatal intensive care unit: a case-control study Outside the hospital, C. parapsilosis can cause nail infections and occasionally skin infections, but these are far less dangerous and far less common as a reason someone would encounter this species name for the first time.
How It Spreads
One of the defining features of C. parapsilosis is the way it moves through a hospital. Studies have found the organism living on the hands of nearly half of healthcare workers sampled in adult ICUs, as well as on surrounding surfaces like sink drains, countertops, and equipment.4PubMed. High colonization by Candida parapsilosis sensu stricto on hands and surfaces in an adult intensive care unit That contamination pattern points to person-to-person transmission rather than something patients carry in on their own. In one early epidemiologic study, researchers found that patients who developed C. parapsilosis infections all had negative cultures when they arrived; the fungus showed up only after admission. Strain typing revealed that the same genetic type appeared in multiple patients, on the hands of several staff members, and on inanimate surfaces, strongly suggesting that healthcare workers’ hands were the bridge.5The American Journal of Medicine. Nosocomial acquisition of Candida parapsilosis: An epidemiologic study
This mode of spread is unusual among Candida species. Most Candida infections come from fungi already living in or on the patient’s own body. C. parapsilosis breaks that pattern because it survives well on skin and dry surfaces, making hand hygiene and environmental disinfection the primary barriers against outbreaks.
Biofilm and Why Catheters Are the Central Problem
The reason C. parapsilosis is so tightly linked to catheters is biofilm. When yeast cells land on the plastic surface of a catheter or other implanted device, they can form a structured community encased in a self-produced matrix. This biofilm acts like a shield, protecting the fungus from antifungal drugs and the immune system alike.6PubMed Central. Genome sequences of six clinical isolates of Candida parapsilosis exhibiting different degrees and temporal regulation of biofilm formation Not every strain builds biofilm equally well; clinical isolates vary from none to heavy biofilm production. But strains that do form thick biofilms are associated with worse outcomes. One study found that among patients infected with high- or moderate-biofilm-forming strains, using azole antifungals alone was linked to higher mortality, while removing the catheter significantly improved survival.7PubMed. Microbiologic and clinical characteristics of biofilm-forming Candida parapsilosis isolates associated with fungaemia and their impact on mortality
Researchers have mapped some of the genetic machinery behind biofilm formation in C. parapsilosis and found that it does not simply mirror what happens in Candida albicans. Several genes that control biofilm growth in C. parapsilosis have little effect on biofilm in C. albicans, and vice versa.8PubMed Central. Comparative Phenotypic Analysis of the Major Fungal Pathogens Candida parapsilosis and Candida albicans That distinction matters because treatments and prevention strategies designed around C. albicans biofilm cannot be assumed to work equally well against C. parapsilosis.
What Infections Look Like
C. parapsilosis causes a range of infections, from superficial to deeply invasive. The most dangerous is candidemia, where the fungus enters the bloodstream. Candidemia typically presents with fever that does not respond to antibiotics, and in severe cases it can seed other organs, causing endocarditis (infection of the heart valves), endophthalmitis (infection inside the eye), septic arthritis, and peritonitis. These deep-seated infections almost always occur in people who have had invasive medical procedures or carry prosthetic devices.9Clinical Infectious Diseases. Candida parapsilosis: Epidemiology, Pathogenicity, Clinical Manifestations, and Antimicrobial Susceptibility
On the milder end, C. parapsilosis can infect nails. Nail infections caused by this organism tend to show up as thickened, discolored nail plates with crumbling or separation of the nail from the nail bed. The discoloration can range from yellowish-brown to unusual greenish-black hues.10Medical Mycology Case Reports. Onychomycosis with greenish-black discolorations and recurrent onycholysis caused by Candida parapsilosis These nail infections are more common in people with underlying health conditions. One documented case involved a patient with liver cirrhosis,11PubMed Central. Candida parapsilosis as a Causative Agent of Onychomycosis in Patient with Cirrhosis of the Liver and another involved a patient with diabetes, both situations that compromise the body’s ability to fight off fungal colonization.12Bioscientia Medicina : Journal of Biomedicine and Translational Research. Menthol-Camphor-Thymol-Eucalyptus Compound as a Novel Adjuvant Therapy in Fluconazole-Treated Candida parapsilosis Onychomycosis: A Case Report
The symptoms of C. parapsilosis infection are not unique to this species. A fever in a catheterized ICU patient could be caused by any number of organisms. That is why laboratory identification is essential for guiding treatment.
How It Gets Identified
Diagnosing a C. parapsilosis infection starts with blood cultures or cultures from the infected site. But simply growing yeast in a culture dish does not tell clinicians which species they are dealing with. Traditional biochemical tests struggle to distinguish C. parapsilosis from its two close relatives, Candida orthopsilosis and Candida metapsilosis, which together form the “C. parapsilosis complex.”13Medical Mycology. Identification and typing of the Candida parapsilosis complex: MALDI-TOF MS vs. AFLP These three species look essentially identical under a microscope but can differ in how they respond to antifungal drugs, so telling them apart has real clinical consequences.
Modern diagnostic labs increasingly use a technology called MALDI-TOF mass spectrometry, which identifies organisms by their protein fingerprint. It works well for distinguishing C. parapsilosis from other Candida species, though earlier versions of its reference databases had gaps when it came to the rarer members of the complex like C. orthopsilosis and C. metapsilosis.14PubMed. Evaluation of the MALDI-TOF VITEK MS™ system for the identification of Candida parapsilosis, C. orthopsilosis and C. metapsilosis from bloodstream infections Molecular methods such as specialized PCR assays can fill that gap when precise species-level identification within the complex is needed.15PubMed Central. Identification and differentiation of Candida parapsilosis complex species by use of exon-primed intron-crossing PCR
Treatment and the Importance of Removing the Catheter
For bloodstream infections, treating the fungus alone is usually not enough. The single most consistently important intervention is pulling out the central venous catheter as quickly as possible. In one study, early catheter removal cut the risk of dying by roughly 70 percent compared to leaving it in place.16PubMed Central. Factors related to outcome of bloodstream infections due to Candida parapsilosis complex In newborns, delayed removal by two or more days has been linked to prolonged bloodstream infection, greater risk of the fungus spreading to the eyes, kidneys, or heart, and worse long-term outcomes including neurodevelopmental problems.17PubMed Central. Candida parapsilosis is a Significant Neonatal Pathogen: A Systematic Review and Meta-Analysis The biofilm sitting on the catheter essentially re-seeds the bloodstream as long as the device stays in.
On the drug side, a network meta-analysis comparing antifungal classes found that echinocandins, particularly caspofungin, offered the best results for reducing 30-day mortality in C. parapsilosis infections.18PubMed Central. Clinical efficacy and safety of antifungal drugs for the treatment of Candida parapsilosis infections: a systematic review and network meta-analysis That may seem counterintuitive, because C. parapsilosis has a naturally occurring genetic quirk in its drug-target gene that makes it less sensitive to echinocandins in laboratory tests compared to other Candida species.19Journal of Antimicrobial Chemotherapy. Genetically related micafungin-resistant Candida parapsilosis blood isolates harbouring novel mutation R658G in hotspot 1 of Fks1p: a new challenge? In practice, though, the doses used clinically appear to overcome that difference, and real-world studies have confirmed echinocandin effectiveness. Fluconazole remains useful for strains that test susceptible, and amphotericin B (especially the liposomal formulation) is an alternative for difficult cases, though its side effects and cost limit routine use.20PubMed Central. Clinical impact of fluconazole-resistant Candida parapsilosis: a narrative review
For rare but severe infections like prosthetic valve endocarditis, where surgery would normally be the standard approach, there are case reports of patients responding to combination antifungal therapy without requiring open-heart surgery. One patient was treated with an echinocandin plus fluconazole, another with an echinocandin combined with flucytosine and fluconazole, both followed by long-term suppressive treatment.21IDCases. Combination antifungal therapy for treatment of Candida parapsilosis prosthetic valve endocarditis and utility of T2Candida Panel®: A case series These are exceptional situations, not standard practice, but they illustrate that medical management can sometimes succeed even in high-stakes infections. Broader testing of antifungal combinations, however, has generally shown that monotherapy remains the better-supported option for most infections.22PubMed. Activity of antifungal agents alone and in combination against echinocandin-susceptible and -resistant Candida parapsilosis strains
The Drug Resistance Problem
Rising resistance to fluconazole is the biggest treatment concern with C. parapsilosis right now. The main mechanisms behind that resistance include changes in the enzyme fluconazole targets and the overproduction of pumps that actively push the drug out of the fungal cell. In one U.S. surveillance study, a specific mutation in the target gene was found in more than half of fluconazole-resistant isolates and in none of the susceptible ones.23PubMed Central. Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system Similar resistant strains carrying the same mutation have been reported in South Korea and elsewhere, suggesting this is not a localized issue.24PubMed Central. Fluconazole-Resistant Candida parapsilosis Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea Precision gene-editing experiments have confirmed that these mutations directly cause reduced susceptibility to fluconazole, removing any doubt about correlation versus causation.25PubMed Central. Precise genome editing underlines the distinct contributions of mutations in ERG11, ERG3, MRR1, and TAC1 genes to antifungal resistance in Candida parapsilosis
Echinocandin resistance is rarer but has appeared, driven by mutations in the same gene region that gives C. parapsilosis its naturally higher baseline tolerance. When those additional mutations stack on top of the existing polymorphism, the result can be clinical failure of echinocandin therapy.26PubMed. Genetic Mutations in FKS1 Gene Associated with Acquired Echinocandin Resistance in Candida parapsilosis Complex The nightmare scenario, which has already occurred in scattered outbreaks, is a strain resistant to both fluconazole and echinocandins, leaving clinicians with amphotericin B as the only reliable remaining drug. Newer antifungal agents including rezafungin, fosmanogepix, and ibrexafungerp have shown promising activity against fluconazole-resistant C. parapsilosis in early testing, but none has yet accumulated the clinical track record to be considered a reliable go-to option.20PubMed Central. Clinical impact of fluconazole-resistant Candida parapsilosis: a narrative review
Preventing Infections in Healthcare Settings
Because C. parapsilosis spreads through contact, prevention centers on hand hygiene, environmental cleaning, and minimizing the time patients spend with central venous catheters. When outbreaks occur, aggressive environmental decontamination has proven effective. During a cluster in a neonatal ICU, infection-control teams disinfected sinks and drains with accelerated hydrogen peroxide, replaced contaminated plumbing components, and used ultraviolet-C irradiation in shared preparation areas. Follow-up cultures from treated surfaces came back clean.27PubMed Central. A cluster of Candida parapsilosis displaying fluconazole-trailing in a neonatal intensive care unit successfully contained by multiple infection-control interventions
Choosing the right antiseptic matters more than you might expect. Laboratory testing of outbreak-associated C. parapsilosis strains grown in dry biofilms found that 70% ethanol and 0.5% chlorhexidine gluconate were the most effective surface disinfectants, achieving large reductions in viable organisms. Povidone-iodine and isopropyl alcohol performed surprisingly poorly in the same model.28Scientific Reports. Tolerance of outbreak-associated Candida parapsilosis isolates to antiseptics in a dry surface biofilm model Hospitals dealing with persistent contamination may need to re-evaluate their standard disinfection protocols with these findings in mind.
How the Immune System Responds
One reason C. parapsilosis is less deadly than C. albicans in many patients is how the immune system handles it. C. albicans is notorious for switching from a round yeast form to an invasive filamentous form that triggers intense inflammation and tissue damage. C. parapsilosis stays in its yeast form, which draws immune cells to the infection site but without provoking the same inflammatory firestorm.29PubMed Central. Intravital Imaging Reveals Divergent Cytokine and Cellular Immune Responses to Candida albicans and Candida parapsilosis Immune cells including neutrophils and macrophages attack the yeast regardless of the inflammatory context, which means that people with functioning immune systems tend to clear C. parapsilosis infections more effectively. That is also why immunocompromised patients face the greatest danger: without an adequate immune response, the organism can persist and disseminate.
Genetic Adaptation to Hospital Environments
C. parapsilosis is not sitting still genetically. Researchers who assembled C. parapsilosis genomes directly from the gut contents of premature infants found that hospital-adapted strains carried multiple copies of a gene involved in lipid transport that has been linked to antifungal resistance. Some strains had as many as 16 copies of this gene, far more than reference strains, suggesting that selective pressure from routine antifungal use in hospitals is reshaping the organism’s genome in real time.30PubMed Central. Genetic and behavioral adaptation of Candida parapsilosis to the microbiome of hospitalized infants revealed by in situ genomics, transcriptomics, and proteomics
Laboratory evolution experiments tell a similar story. When C. parapsilosis strains were repeatedly exposed to echinocandins in controlled settings, they developed resistance mutations, but those mutations came with a tradeoff: the resistant strains showed weakened virulence in animal models and changes in how their cell walls were constructed.31PubMed Central. Echinocandin-Induced Microevolution of Candida parapsilosis Influences Virulence and Abiotic Stress Tolerance Whether that tradeoff holds in real patients is uncertain, but it offers a sliver of reassurance that resistance may not always come for free from the fungus’s perspective.
C. Parapsilosis Outside the Hospital
Though it is primarily a healthcare-associated pathogen, C. parapsilosis has a life outside hospitals too. Researchers studying wild and semi-urban birds found the organism in the droppings of several species, including waxwings, jays, and magpies. In some bird species, C. parapsilosis made up a substantial portion of the yeast found in their feces. The concern is that birds living near urban areas could pick up drug-exposed strains from human environments and carry them into natural ecosystems, potentially spreading resistant organisms beyond the clinical setting.32PubMed. Wild and partially synanthropic bird yeast diversity, in vitro virulence, and antifungal susceptibility of Candida parapsilosis and Candida tropicalis strains isolated from feces This is an emerging area of research, not yet a demonstrated public health crisis, but it underscores that antifungal resistance is not a problem confined to hospital walls.